RTI Biologics (Nasdaq: RTIX) reported earnings on Jan. 31. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), RTI Biologics beat expectations on revenues and earnings per share.

Compared to the prior-year quarter, revenue shrank and GAAP earnings per share shrank.

Gross margins increased, operating margins grew, and net margins dropped.

Revenue details
RTI Biologics tallied revenue of $42.9 million. The six analysts polled by S&P Capital IQ foresaw revenue of $41.2 million. Sales were 5.4% lower than the prior-year quarter's $45.4 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.

EPS details
EPS came in at $0.04. The six earnings estimates compiled by S&P Capital IQ predicted $0.03 per share. GAAP EPS of $0.04 for Q4 were 33% lower than the prior-year quarter's $0.06 per share.

Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 46.2%, 170 basis points better than the prior-year quarter. Operating margin was 8.4%, 70 basis points better than the prior-year quarter. Net margin was 5.5%, 60 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $42.0 million. On the bottom line, the average EPS estimate is $0.03.

Next year's average estimate for revenue is $176.0 million. The average EPS estimate is $0.17.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 211 members out of 222 rating the stock outperform, and 11 members rating it underperform. Among 56 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 55 give RTI Biologics a green thumbs-up, and one gives it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on RTI Biologics is outperform, with an average price target of $4.85.

Over the decades, small-cap stocks like RTI Biologics have produced market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.